GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Scaled Net Operating Assets

Prestige Biologics Co (XKRX:334970) Scaled Net Operating Assets : 0.64 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Prestige Biologics Co's operating assets for the quarter that ended in Dec. 2024 was ₩276,011 Mil. Prestige Biologics Co's operating liabilities for the quarter that ended in Dec. 2024 was ₩61,394 Mil. Prestige Biologics Co's Total Assets for the quarter that ended in Sep. 2024 was ₩335,338 Mil. Therefore, Prestige Biologics Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.64.


Prestige Biologics Co Scaled Net Operating Assets Historical Data

The historical data trend for Prestige Biologics Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co Scaled Net Operating Assets Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Jun24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only 0.31 2.95 1.07 0.83 0.70

Prestige Biologics Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.69 0.73 0.77 0.64

Competitive Comparison of Prestige Biologics Co's Scaled Net Operating Assets

For the Biotechnology subindustry, Prestige Biologics Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Biologics Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prestige Biologics Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Prestige Biologics Co's Scaled Net Operating Assets falls into.


;
;

Prestige Biologics Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Prestige Biologics Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2024 )
=(Operating Assets (A: Jun. 2024 )-Operating Liabilities (A: Jun. 2024 ))/Total Assets (A: Jun. 2023 )
=(259906.814-44688.892)/305753.043
=0.70

where

Operating Assets(A: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=289414.061 - 29507.247
=259906.814

Operating Liabilities(A: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=217731.939 - 125426.146 - 47616.901
=44688.892

Prestige Biologics Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(276010.719-61394.053)/335337.56
=0.64

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=292063.275 - 16052.556
=276010.719

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=150952.194 - 38110.96 - 51447.181
=61394.053

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Biologics Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Prestige Biologics Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Biologics Co Business Description

Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co Headlines

No Headlines